Nikolai Nikolaevich Anitschkow (In Commemoration of the 90th Anniversary of his Birthday)

Khavkin, T. N.

doi:10.1016/s0005-8165(75)80042-4

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the early 1900s, a German chemist named Adolph Windaus determined atheromatous plaque from human aortas contained 20-fold higher concentrations of cholesterol than normal aortas. Soon after, the Russian pathologist Nikolai Anitschov strengthened this observation by feeding rabbits a high-cholesterol diet and creating the fi rst animal model of atherosclerosis (Khavkin et al 1975;Vance et al 2000). In 1955, a biophysicist named John Gofman used ultracentrifugation to separate plasma lipoproteins by density and correlated risk of myocardial infarction (MI) with elevated low-density lipoprotein cholesterol (LDL-C) levels.…”

Section: Introductionmentioning

confidence: 99%

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease

Kapur¹

2008

VHRM

View full text Add to dashboard Cite

Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one's risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifi cally regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL's ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.

show abstract

Section: Introductionmentioning

confidence: 99%

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease

Kapur¹

2008

VHRM

View full text Add to dashboard Cite

show abstract

Animal Models of Atherosclerosis

Steinberg

2007

The Cholesterol Wars

View full text Add to dashboard Cite

Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease

Kapur

2007

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Since the identification of a fungal metabolite that inhibits HMG-CoA reductase in 1976, statins have emerged rapidly as the global leader in pharmacotherapeutics designed to lower low-density lipoprotein cholesterol (LDL-C). In conjunction, practice guidelines have recommended increasingly aggressive measures to improve coronary heart disease (CHD) outcomes by lowering LDL-C. By virtue of unique chemical characteristics, enhanced binding thermodynamics and limited cytochrome P450 3A4 metabolism, rosuvastatin calcium has a safety profile in line with currently marketed statins, but a different efficacy profile. Mirroring this chemical profile, the GALAXY program represents a comprehensive evaluation of the efficacy, safety and cost-effectiveness of rosuvastatin in individuals representing various clinical diagnoses, pathophysiological states and ethnicities. Also results from the Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study could provide further evidence for the use of rosuvastatin in individuals with traditional and emerging CHD risk factors, such as an elevated high sensitivity C-reactive protein level. This review will provide a comprehensive evaluation of the chemistry, clinical efficacy, safety and tolerability of rosuvastatin, and discuss the future role in the management of CHD and atherosclerosis.

show abstract

Nikolai Nikolaevich Anitschkow (In Commemoration of the 90th Anniversary of his Birthday)

Cited by 4 publications

References 1 publication

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease

Animal Models of Atherosclerosis

Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease

Contact Info

Product

Resources

About